September 16, 2024

Immunotherapy after surgery helps people with high-risk bladder cancer live cancer-free longer – National Institutes of Health (NIH) (.gov)

September 16, 2024

Dr Friedlander on AEs Associated With Enfortumab Vedotin in Bladder Cancer – OncLive

September 16, 2024

Durvalumab regimen improves outcomes in muscle-invasive bladder cancer – Healio

September 15, 2024

NEJM at ESMO — Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma

New England Journal of Medicine, Ahead of Print.

September 15, 2024

NEJM at ESMO — Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

New England Journal of Medicine, Ahead of Print.